JERUSALEM, April 18 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (FTSE: OJU) invites everybody to join Nadav Kidron on www.Wallst.net to discuss the future of Oramed Pharmaceuticals Inc., and update the investment community on the present status of the company. The interview will take place at 3pm Eastern time on Thursday, April 19. It will be broadcast live on their website and then archived into their records for future reference. If you have any specific questions to be asked, please email them to info@oramedpharma.com and they will be forwarded on Thursday morning to the interviewer.
To hear the interview in its entirety, please visit http://www.wallst.net/ and click on “Interviews”. The interview can be accessed either by locating the Company’s ticker symbol (ORMP) under the appropriate exchange (OTCBB) on the left-hand column of the “Interviews” section of the site, or by entering the Company’s ticker symbol in the Search Archive window.
CEO Nadav Kidron stated, “I look forward to hearing a public response to our company’s efforts and successes over the past year.”
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals Inc. is an Israeli company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website at www.oramedpharma.com
Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute “forward- looking statements”. Those statements include statements regarding the intent, belief or current expectations of Oramed as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that we are currently developing an orally soft gel insulin capsule for the treatment of diabetes; and that we are also pursuing the development of oral delivery solutions for other drugs and vaccines. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development; we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patents may be subsequently shown to be invalid or infringe the patents of others; we may be unable to attract or retain our key employees, consultants and advisors, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialize our future products. Readers should refer
to our most recent 10-KSB filed on Edgar and the 8-K announcing our acquisition of the Oramed technology filed March 8, 2006.
Oramed Pharmaceuticals, Inc.
CONTACT: Vinisha Agnihotri of Oramed Pharmaceuticals, Inc.,+1-646-467-2252, info@oramedpharma.com
